Resonance Health is happy to provide you with our latest quarterly newsletter where you can find an update on our busy end to 2015. To read the newsletter please click here We would like to take this opportunity to wish everyone a happy holidays and a safe and healthy 2016!
Resonance Health News December 2015 Read More »
FerriScan R2-MRI is now the recognised global gold standard in measurement of liver iron concentration. It has largely replaced liver biopsy in many countries, saving patients the discomfort and risks associated with invasive procedures. The scientific rigor underpinning FerriScan’s calibration and validation, together with the quality-assured service delivery, means that clinicians now confidently use the reported
FerriScan Case Study Challenge Read More »
Resonance Health is exhibiting at the American Society of Hematology (ASH) Conference in Orlando Florida from 5 – 8 December.
30,000 FerriScans and ASH Read More »
Resonance Health is happy to provide you with an update on our recent activity via our latest quarterly newsletter. To read the newsletter please click here
Resonance Health News September 2015 Read More »
Resonance Health is pleased to announce the appointment of KNS in Canada who will launch a local presence for FerriScan at the forthcoming 2015 Pan-Canadian Thalassemia Conference taking place in Toronto on September 25-26th.
Resonance Health Appoints New Distributor, KNS in Canada Read More »
St Mary’s Hospital has become one of the first hospitals in Europe to reach a milestone of providing 1000 FerriScans (the Gold Standard for measuring Liver Iron Concentration) for children and adult patients.
St Mary’s Hospital Celebrates 1000 FerriScans From Perth to Paddington! Read More »
We are excited to announce that the paediatric fatty liver disease study using HepaFat-Scan has now commenced in the USA. It is being run in collaboration with the prestigious children’s hospital, Children’s Healthcare of Atlanta. At the date of this release, approximately ten patients have already been recruited and had HepaFat-Scans completed for the study, which
HEPAFAT-SCAN® FATTY LIVER STUDY COMMENCES IN THE USA Read More »
Congratulations to our Chief Scientific Officer, Professor Tim St Pierre, for winning the Technology category of the Western Region EY Entrepreneur of the Year™ award on behalf of Resonance Health!
Entrepreneur of the Year Award – Western Region Technology Winner! Read More »
The symposia on Non-alcoholic Fatty Liver Disease (NAFLD) in Shanghai was co-organised by the China Medical Association and Zhongshan Hospital Fudan University, chaired by Prof Gao Xin.
Conference Update: China Symposium on NAFLD in Shanghai Read More »
Resonance Health attended or exhibited at three conferences in Europe in June 2015. We profiled both our FerriScan® and HepaFat-Scan® technologies to thousands of delegates and generated almost a hundred leads from around the world.
Conference Update: Showcasing Resonance Health in Europe Read More »
INVESTORS
SUPPORT
PATIENTS
PHYSICIANS